ABT stock price remains resilient despite sector headwinds. Increased adoption of Abbott's continuous glucose monitoring devices positions the company favorably amidst rising demand for diabetes management solutions worldwide. Investors will be eagerly watching for the performance of Abbott in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 15, 2025. The company is predicted to post an EPS of $1.3, indicating a 7.44% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.42 billion, indicating a 7.4% increase compared to the same quarter of the previous year. These are just a few of the metrics contributing to NVST's Value grade of B and ABT's Value grade of C. ABT stock price stability over the past weeks has attracted yield-focused investors. Dividend payout ratio remains sustainable, with free cash flow coverage comfortably exceeding industry standards.